Field of Research (FoR)
Dr Wasinger's research focuses on the advancement of analytical techniques fostering accurate and sensitive measurement of peptides and proteins within the context of mass spectrometry based analysis of the proteome. She is keenly interested in improving detection of low mass, endogenous proteins and peptides and translating this into tangible methods to deepen understanding of biological processes. Her research focuses on a variety of medical...view more
Dr Wasinger's research focuses on the advancement of analytical techniques fostering accurate and sensitive measurement of peptides and proteins within the context of mass spectrometry based analysis of the proteome. She is keenly interested in improving detection of low mass, endogenous proteins and peptides and translating this into tangible methods to deepen understanding of biological processes. Her research focuses on a variety of medical diseases and biochemistries, as well as all techniques relating to proteomic and metabolomic analysis, and quantitation.
Dr Wasinger is recognised in the field of proteomics, most notably, as the first author on the foundation paper describing the term ‘proteomics’. This work was a collaboration between Sydney, NSW and Macquarie Universities and the key players in the field, including Marc Wilkins who coined the term. It was this paper that was the very first to define proteomics and apply this field of research to a model organism- Mycoplasma genitalium (Wasinger et. al. 1995).
As described in the publication; the field uses a combination of techniques, and Wasinger’s research has always centred on expanding the boundaries through complementary methods to characterise the proteome. This work has been built on with continued research in: the first ‘complete’ proteome available for life at its most basic: M.genitalium (Wasinger et.al 2000); the international effort and first publication of the human plasma proteome (Omenn et al., 2005, Wasinger et al., 2005).
Her recent work has led to two patents. This application is the culmination of many years of collaborative research and has resulted in the successful development of new technology in association with an Australian Biotech company and publications describing the enrichment of low mass proteins. This work was then validated by biological application on IBD. She has expertise in the translation of discovery research into clinically useful products; experience in the application of next generation life science ‘-omics’ technologies; partnerships, collaborations, project management, licensing and commercialisation. Collaborating groups range from national and international universities as well as medical institutes.
Proteomics is an evolving field with rapid expansion into new areas, new technologies and continually moving waves of thought. Dr Wasinger is recognised internationally and is a reviewer for proteomic and gastroenterology journals and has also been associate editor of International Journal of Proteomics; and Journal of Integrated ‘Omics and has co-edited a special issue on Quantitative Mass spectrometry (2013).
Dr Wasinger has been an organising member of an international conference, HUPO2010 and was nominated chair of the education day and convenor of the day at Darling Harbour Convention Centre 2010.
My Research Supervision
Areas of supervision
ILP, Honours, PhD